First the withdrawal of prescription MiraLAX last November was a major disruption in this category. Not only are patients now seeking different prescription options but physicians are choosing LINZESS for more of their IBS-C and chronic constipation patients. And this seems to be having a lasting effect contributing to the strong LINZESS growth that we have seen this year. Regarding our Phase III abdominal symptom data in July our sales force began communicating to physicians about the benefit LINZESS delivered in relieving overall abdominal symptoms of bloating pain and discomfort in patients with IBS-C. We also refreshed our consumer materials in September to include disease state information about IBS-C including a reference to the abdominal symptoms including bloating and discomfort.